Loading provider…
Loading provider…
Surgery Physician in New York, NY
NPI: 1124019815Primary Employer
Mskcc Surgery Group
mskcc.org
HQ Phone
Get MD Vivian's Phone NumberMobile
Get MD Vivian's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
FL State Medical License
2023
NY State Medical License
1999 - 2026
NJ State Medical License
2021 - 2025
CT State Medical License
2023 - 2024
WI State Medical License
2002 - 2017

American Board of Surgery
Surgery
NewYork-Presbyterian/Columbia University Irving Medical Center
Advanced Laparoscopic Surgery • 2004 - 2005
2004 - 2005
New York Presbyterian Hospital (Cornell Campus)
Residency • Surgery
1997 - 2004
Weill Cornell Medicine
weill.cornell.edu
Medical School
Until 1997
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 160 | 193 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 103 | 103 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 64 | 69 |
| 4 | 43239Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | 33 | 33 |
| 5 | 49321Biopsy of abdomen using an endoscope | 29 | 29 |
Laparoscopic adrenalectomy for isolated adrenal metastasis.
Authors: Caner Dinlenc, Yuman Fong, Laura Tang, Eric Gerber, Karim Touijer, Michael D'Angelica
Journal: JSLS
Esophageal reinforcement with an extracellular scaffold during total gastrectomy for gastric cancer.
Authors: Yelena Janjigian, Cheguevara Afaneh, Mark Schattner, Sam Yoon, David Ilson
Journal: Ann Surg Oncol
Publication Date: 2014-10-16
Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) Variant.
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Merck Sharp & Dohme LLC, Genentech, Inc.
Intervention / Treatment: DRUG: Docetaxel, DRUG: Trastuzumab, DRUG: Capecitabine, DRUG: Pembrolizumab, DRUG: Oxaliplatin, DRUG: 5-Fluorouracil
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Intervention / Treatment: OTHER: MDASI-GI
Lead Sponsor: M.D. Anderson Cancer Center
Intervention / Treatment: OTHER: Standard of Care, OTHER: Control Group